Apogee Therapeutics 주식 (NASDAQ: APGE)

에 대한 최신 뉴스 Apogee Therapeutics (NASDAQ:APGE) 주식

APOGEE THERAPEUTICS INC

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

QuantumScape QS Stock

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Apogee Therapeutics Inc

DINO

HF Sinclair Dual Lists On NYSE Texas

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 33.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 15.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 9.80% at $8.67</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 9.56% at $0.51</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 9.52% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 7.49% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 7.42% at $0.84</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 6.74% at $3.64</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 6.00% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 5.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 4.58% at $5.25</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.49% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 3.10% at $0.54</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 19.10% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 12.56% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 11.96% at $0.23</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 10.00% at $0.0009</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 9.80% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 5.56% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/IIPR">Innovative Ind Props</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) shares closed down 3.63% at $56.76</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BLGVF

CBDY

CNBX

CNTMF

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

FUAPF

GBHPF

GNLN

GTBIF

IIPR

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

OILFF

RMHB

SOLCF

TCNNF

ZDPY

Cannabis Stock Gainers And Losers From June 25, 2025

Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 5 years by 7.99% on an annualized basis producing an average annual return of 22.5%. Currently, Apollo Asset Management has a market capitalization of $78.71 billion. 
Buying $1000 In APO: If an investor had bought $1000 of APO stock 5 years ago, it would be worth $2,876.57 today based on a price of $137.73 for APO at the time of writing.
<h3>Apollo Asset Management's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750883418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Apollo Asset Management Stock In The Last 5 Years

Compass Diversified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CODI#NYSE">CODI</a>) ("CODI") today disclosed non-reliance on its financial statements for fiscal years 2022 and 2023 amid an ongoing investigation into its subsidiary Lugano Holding, Inc.&nbsp;("Lugano"). This follows CODI's May 7 disclosure concerning non-reliance on its 2024 financial statements. As previously disclosed, the investigation has preliminarily identified irregularities in Lugano's financing, accounting, and inventory practices.
CODI is focused on completing the investigation, which is progressing in line with expectations, and actively working to finalize the necessary financial restatements. Importantly, the investigation is focused on Lugano and does not involve any of CODI's other subsidiaries.

Earnings

CODI

Compass Diversified Deems 2022 And 2023 Financials Unreliable Amid Ongoing Investigation Into Subsidiary Lugano Holding

WIIM

GLNG

Golar LNG shares are trading lower after the company announced plans to offer $500 million in aggregate principal amount of convertible senior notes due 2030.

Footwear and apparel leader Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) could highlight a continued turnaround effort and its go-forward growth strategy when it reports fourth-quarter financial results after <a href="https://www.benzinga.com/earnings" target="_blank" rel="noopener">the market closes on</a><a href="https://www.benzinga.com/earnings"> Thursday.</a>
Here's a look at the analyst estimates, what experts are saying and key items to watch.
Earnings Estimates: Analysts expect Nike to report fourth-quarter revenue of $10.71 billion, down from $12.61 billion in last year's fourth quarter, according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625"> from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in two straight quarters and beaten estimates in six of the last 10 quarters overall.
Analysts expect Nike to report fourth-quarter earnings per share of 12 cents, down from 99 cents per share in last year's fourth quarter.
The company has beaten analyst estimates for earnings per share in seven straight quarters and nine of the last 10 quarters.
Read Also: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/45730063/new-etfs-let-investors-mirror-buffett-ackman-burrys-top-stock-trades">New ETFs Let Investors Mirror Buffett, Ackman, Burry&#8217;s Top Stock Trades</a>
What Experts Are Saying: Investors who are looking to buy Nike stock may want to wait until after the dust settles from the latest earnings report.
"Nike has traded lower after eight of its last nine earnings reports, including the last six in a row," Freedom Capital Markets Chief Global Strategist Jay Woods said in a weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
Woods said Nike stock is down 66% from its all-time high in 2021.
"Earnings have not been good to the iconic sports brand. Shareholders have been anxiously waiting for new management to turn things around, but high inventories and now tariff concerns have stymied any sense of a sustainable rally."
Looking at the stock chart, Woods said "things aren't looking good."
"For this stock to finally reverse it needs more time and a few quarters of solid growth. It may be wiser trying to buy shares on a breakdown towards its lows around $52."
Needham analyst Tom Nikic said Nike stock could have modest upside in the fourth-quarter earnings, but the turnaround efforts are not over, in<a href="https://www.benzinga.com/news/25/06/45998126/nike-expectations-too-high-analyst-cuts-price-target-ahead-earnings"> a recent note.</a>
The analyst maintained a Buy rating, while reducing the price target from $75 to $66.
Nikic said estimates for the fourth quarter are conservative, while Street expectations for the next fiscal year are "too high" due to the impact of tariffs.
"While we believe that last year's change in leadership will eventually lead to brighter days for Nike, the company still has a lot of work to do to reignite brand heat and clean up the marketplace," Nikic said.
Bank of America Securities analyst Lorraine Hutchinson said Nike's fourth quarter could be the "peak" of sales and margin pressure in<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45932987/nike-q4-earnings-analyst-pain-2026-gain"> a recent note.</a>
The analyst reiterated a Buy rating with an $80 price target on Nike.
Hutchinson said Nike's Spring '26 Innovation pipeline is strong, and Nike is in a good position to navigate wholesale challenges. The analyst said Nike can grow retail relationships and its shelf space as competitors scale back.
Here are other recent<a href="https://www.benzinga.com/quote/NKE/analyst-ratings"> analyst ratings on Nike </a>and their price targets:
<ul class="wp-block-list">
<li>Truist: Maintained Buy rating, lowered price target from $82 to $73</li>
<li>Evercore ISI Group: Maintained Outperform rating, lowered price target from $97 to $75</li>
<li>Deutsche Bank: Maintained Buy rating, lowered price target from $77 to $71</li>
<li>Barclays: Maintained Equal-Weight rating, lowered price target from $60 to $53</li>
</ul>
Key Items to Watch: Nike's <a href="https://www.benzinga.com/generalsports/25/03/44426104/nike-q3-earnings-revenue-beat-eps-beat-inventories-down-2-we-are-on-the-right-path">third quarter results </a>saw the North American sector (-4%) with the lowest year-over-year decline of the segments, while Greater China's 17% decline was the worst.
Investors will closely watch these two regions to see if trends continue and Nike gets closer to year-over-year breakeven.
Investors and analysts will likely want an update on the company's growth plans and several recent announcements.
In May, Nike announced it would begin selling on Amazon.com for the first time in six years. The move could mark a shift in Nike's future as it previously focused on selling directly to customers and likely saw Amazon as a competitor in the ecommerce space.
Nike announced a collaboration with Kim Kardashian's SKIMS brand in February but later announced it was delaying the launch. Investors and analysts could get an update on this new collaboration and how it could help Nike grow and reach new customers.
NKE Price Action: Nike stock was down 0.9% to $60.83 on Wednesday versus a 52-week trading range of $52.28 to $94.74. Nike stock is down 17.7% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45807588/bernie-sanders-slams-nike-company-makes-23-billion-a-year-workers-make-202-a-month-corporate-greed-at-its-worst">Bernie Sanders Slams Nike: Company Makes $23 Billion A Year, Workers Make $202 A Month—&#8217;Corporate Greed At Its Worst&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Previews

Analyst Ratings

Nike Q4 Earnings Preview: Market Expert Says 'Things Aren't Looking Good'

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001996192/000121390025057783/ea0246970-8k_lakeside.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/0001996192/000121390025057783/ea0246970-8k_lakeside.htm</a>

Lakeside Holding Enters Securities Purchase Agreement With Certain Investors For Private Placement Of 3M Shares

Worthington Steel shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

Kymera Therapeutics shares are trading lower after the company announced a $250 million public offering.

MLKN

MillerKnoll shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

The last frontier is now an opportunity for finance. Once the playground of state space agencies, the region has turned into a robust environment for private enterprise, ranging from agile satellite-launch ventures to ambitious space-tech platforms. The industry has been warming up for quite some time, but it&#8217;s recent developments such as the Rocket Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46096249/rocket-lab-stock-hits-new-all-time-high-whats-fueling-the-momentum">stock&#8217;s record high</a> and growing launch schedule have reminded investors of their interest.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/46090686/europes-navigation-future-takes-flight-with-rocket-lab-electron">Europe&#8217;s Navigation Future Takes Flight With Rocket Lab Electron</a>
PwC&#8217;s <a href="https://www.pwc.com/us/en/industries/industrial-products/library/space-industry-trends.html#:~:text=Future%20projections%20suggest%20that%20the,launches%20never%20exceeded%20170%20objects.">prediction </a>that the global space economy might turn into a $2 trillion market by 2040 is now not a far-off dream, and it&#8217;s a call to action for thematic investors. But here&#8217;s the surprise: although standalone space stocks have been red-hot, <a href="https://www.benzinga.com/etfs">space-themed ETFs</a> aren&#8217;t so much on the same rocket.
<h2 class="wp-block-heading">ETFs In Orbit</h2>
With Rocket Lab blazing a trail, thematic ETFs in the space sector can be the next stop. 
The Procure Space ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) are the two primary space-themed ETFs available to investors, which carries Rocket Lab. RKLB is the largest holding in AEKX, and currently the third largest holding in UFO.
UFO has an expense ratio of 0.94%, and ARKX, 0.75%. The ETFs are up 3.15% and 3.64%, respectively, in the past five days.
<h2 class="wp-block-heading">Rocket Lab&#8217;s Rally: A Shot Across The Bow</h2>
Rocket Lab saw its <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46096249/rocket-lab-stock-hits-new-all-time-high-whats-fueling-the-momentum">shares shoot to $33.46</a>, an all-time high, on Tuesday, boosted by optimism and increasing operational traction. The business model is slim and diversified. It launches tiny satellites today but is busy breaking into satellite parts, monitoring services, and developing its next-generation Neuron rocket.
Shares surged after announcements of:
<ul class="wp-block-list">
<li>A new two-mission contract for Electron rockets committed in June 2025.</li>
<li>The maiden deployment of a SAR satellite for iQPS—its 66th launch ever.</li>
<li>Bullish analysts&#8217; upgrades: Cantor Fitzgerald upgraded its price target to $35 on the basis of strategic execution and Stifel reaffirmed a $34 target, pointing towards Neutron&#8217;s potential.</li>
</ul>
In brief, Rocket Lab intends to be the Amazon Web Services of orbit—design it, launch it, operate it.
<h2 class="wp-block-heading">Bottom Line</h2>
The space economy is no longer&nbsp;fiction, it&#8217;s investable, and it&#8217;s&nbsp;taking&nbsp;off. Rocket Lab&#8217;s&nbsp;rise indicates&nbsp;what&nbsp;can&nbsp;be achieved&nbsp;when execution&nbsp;and&nbsp;ambition&nbsp;converge&nbsp;in the space&nbsp;competition.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/space/25/06/46002335/rocket-lab-stock-is-on-investor-radars-whats-going-on">Rocket Lab Stock Is On Investor Radars: What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

ETFs

ARKX

RKLB

Rocket Lab's Record-Smashing Rally: UFO And ARKX ETFs In Focus

The special committee (the "Special Committee") of the Board of Directors (the "Board") of WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>), a leading technology and software infrastructure provider to the cannabis industry, today confirmed that it received a letter, dated June 23, 2025, from Douglas Francis, a founder, Chief Executive Officer and Chairman of the Board, Justin Hartfield, a founder and stockholder of WM Technology, and entities affiliated with Messrs. Francis and Hartfield, pursuant to which Messrs. Francis and Hartfield communicated that (1) due to certain external factors they must withdraw their non-binding proposal, dated December 17, 2024, to purchase all of the outstanding common stock (Class A and Class V) of WM Technology not already beneficially owned by Messrs. Francis and Hartfield for $1.70 per share of WM Technology common stock and (2) Messrs. Francis and Hartfield will continue to evaluate a transaction and may submit an alternative proposal.
There can be no assurance that Messrs. Francis and Hartfield will submit a subsequent proposal, any definitive agreement will be executed, or the proposed transaction or any other transaction will be approved or consummated. The Special Committee does not intend to comment on or disclose further developments regarding any potential transaction unless and until it deems further disclosure is appropriate or required.
The Special Committee remains committed to acting in the best interests of WM Technology and all of its stockholders.
The Special Committee has retained Evercore Group L.L.C. as its independent financial advisor and Allen Overy Shearman Sterling US LLP as its independent legal advisor.

Management

MAPS

WM Technology Founders Withdraw $1.70 Per Share Buyout Proposal

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036125023648/ef20051087_8k.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036125023648/ef20051087_8k.htm</a>

Opus Genetics Nirav Jhaveri Departs As CFO; Amy Rabourn To Serve As Interim CFO And Principal Accounting Officer

HIVE Digital Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is <a href="https://www.benzinga.com/quote/HIVE/news">charging ahead with plans</a> to nearly triple its hashrate to 25 EH/s by the fourth quarter of 2025. But while the ambition is clear, the execution risks are anything but negligible — especially in Paraguay, where much of this growth is concentrated.
Read Also: <a href="https://www.benzinga.com/25/04/44895610/hive-powers-up-new-100mw-facility-sets-stage-for-25-ehs-bitcoin-blitz">HIVE Digital Energizes Paraguay Site With Major Bitcoin Mining Expansion</a>
<h1 class="wp-block-heading">Big Ambitions, Bigger Bottlenecks?</h1>
"Scaling to 25 EH/s is an ambitious goal. While we're on track, there are always execution risks," says CFO Darcy Daubaras in an exclusive email interview with Benzinga. Among them: hardware shipping delays, global supply chain snags and construction setbacks.
HIVE is betting on Paraguay's abundant hydropower and favorable climate to drive efficient mining. But can the country's infrastructure keep up with HIVE's scale-up?
Daubaras acknowledges the challenges. "Risks do exist. These include regulatory changes, limitations in grid infrastructure, and dynamics of regional trade." 
In other words, even the most miner-friendly environment can pose headaches when you&#8217;re building out industrial-scale data centers.
<h1 class="wp-block-heading">A Local Edge &#8211; But Is It Enough?</h1>
To mitigate the risk of the ramp-up, HIVE has boots on the ground. Its president in Paraguay, Gabriel Lamas, is a veteran electrical engineer who previously held key roles at Bitfarms and Paraguay's national utility, ANDE. Under his leadership, HIVE is focusing on grid integration, reliability, and energy optimization.
"His deep technical knowledge and proven track record in energy optimization ensure we maintain HIVE's high standards as we scale in South America," says Daubaras.
Still, the question lingers: Can Paraguay deliver the power, political stability and grid reliability needed to keep the lights on at 25 EH/s?
If the answer is yes, HIVE may emerge as one of the most efficient and greenest miners on the planet. If not, the hashrate dream could hit an electric wall.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46096008/cathie-woods-2030-math-tesla-rockets-past-spacex-by-5-7t">Cathie Wood&#8217;s 2030 Math: Tesla Rockets Past SpaceX By $5.7T</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Global

Exclusives

Interview

HIVE

EXCLUSIVE: HIVE's Bitcoin Ambitions Are Exploding — But Can The Grid Keep Up?

RVPH

Reviva Pharmaceuticals shares are trading lower after the company announced a proposed public offering.

Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) shares traded higher Wednesday, and JPMorgan weighed in on the stock.
What To Know: In the note, the analyst was surprised by Bumble's 30% workforce reduction and even more so by the company's upward revision to its second-quarter revenue and adjusted EBITDA guidance. 
Despite cutting $20 million in marketing spend, Bumble raised its revenue outlook to $244 million to $249 million, up from $235 million to $243 million previously.
The stronger outlook comes as a surprise given that Bumble app downloads are down more than 30% year-over-year. The analyst suggested the full revenue impact of lower marketing spend may still be delayed, as new users often take time to convert into paying subscribers.
Although the workforce cut was larger than expected, Bumble plans to reinvest most of the $40 million in expected annual savings into product and technology. The analyst noted that with Bumble now operating at a margin level similar to Match Group, there may be limited room for further cost-cutting.
Still, JPMorgan cautioned investors not to assume that the improved guidance signals a rebound in the online dating market. Tinder's monthly active users remain stagnant, and Bumble's download trends continue to decline.
BMBL Price Action: Bumble stock closed Wednesday 25.14% higher at $6.52, according to data from <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
See Also: • <a href="https://www.benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny">Did The FDA Make A Mistake? Sarepta&#8217;s Elevidys Approval Under Scrutiny</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

BMBL

Bumble Defies Download Drop With Strong Outlook As Stock Soars

Bit Digital, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) ("Bit Digital" or the "Company"),&nbsp;today announced that its wholly-owned HPC subsidiary, WhiteFiber Inc. ("WhiteFiber"), has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of WhiteFiber's ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is subject to market and other conditions and the completion of the SEC's review process.

IPOs

BTBT

Bit Digital's Subsidiary WhiteFiber Confidentially Files for IPO with SEC

Burcon NutraScience (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BU#TSX">BU</a>) reported quarterly losses of $(0.23) per share. This is a 1050 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $43.000 thousand in sales this quarter.

TSX:BU

Burcon NutraScience Q4 EPS $(0.23) Down From $(0.02) YoY, Sales $43.000K

Nature's Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) ("Nature's Sunshine" or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the "Selling Stockholder").
The Selling Stockholder will receive all of the net proceeds from the offering. Nature's Sunshine is not selling any shares of common stock in the offering and will not receive any proceeds from the offering. The Selling Stockholder will pay any underwriting discounts and commissions and transfer taxes attributable to the resale of the shares of the Company's common stock the Selling Stockholder holds, as well as certain reasonable out-of-pocket expenses incurred by the underwriter. The Company will bear all other costs, fees and expenses incurred in effecting the registration of the shares in the offering.
As part of the offering, the Company has agreed with the Selling Stockholder that it may purchase up to $15.0 million of the shares of its common stock that are subject to the offering from the underwriters at the public offering price as part of the Company's previously announced share repurchase program. However, the Company has not agreed to purchase a minimum amount of shares and may determine to purchase fewer or no shares in this offering. Accordingly, there can be no guarantee that the Company will purchase any shares in this offering and investors should not rely on such agreement as evidence that this offering is more likely to be successful. The Company anticipates that the stock repurchase, if any, would be funded from cash on-hand and funds drawn from its credit facility.
D.A. Davidson &amp; Co. is acting as sole book-running manager and representative of the underwriters for the offering.

Offerings

NATR

Nature's Sunshine Launches Secondary Offering Of 2.85M Shares By Fosun Pharma; Company May Repurchase Up To $15M Under Existing Buyback Program

<a href="https://www.bloomberg.com/news/articles/2025-06-25/fannie-freddie-ordered-to-find-ways-to-count-crypto-as-an-asset?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-06-25/fannie-freddie-ordered-to-find-ways-to-count-crypto-as-an-asset?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-25/fannie-freddie-ordered-to-find-ways-to-count-crypto-as-an-asset?srnd=homepage-americas</a>

FMCC

FNMA

Reported Earlier: 'Fannie, Freddie Ordered To Find Ways To Count Crypto As An Asset' -Bloomberg

Press Releases

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Health Care

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Arcellx

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CG Oncology

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

ImmunityBio

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

Citigroup

Wedbush

Canaccord Genuity

B of A Securities

Jefferies

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">전고체 배터리 산업화</a> 계약을 체결했다고 발표한 후 64.34% 급등했다.</li>
<li>랜티우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)의 주가는 전문 <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">진단 방사성 의약품</a>에 대한 지불 개선을 위한 CMS 제안 이후 55.93% 급등했다.</li>
<li>선런(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)의 주가는 37.59% 상승했다. 최근 CPI 데이터에 따라 더 넓은 산업 분야의 기업 주가가 상승했기 때문이다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>)의 주가는 화농한선염과 아토피성 피부염에 대한 임상 2상을 확대해 <a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener">안전성 및 유효성</a>에 대한 중간 검토를 거쳐 중추적 연구로 보다 신속하게 진행하겠다는 의사를 밝힌 뒤 37.38% 상승했다.</li>
<li>아포지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)의 주식은 35.68% 급등했다.</li>
<li>조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>)은 회사가 <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">물을 유일한 부산물</a>로 사용하여 523마일을 수소 전기 항공 택시 시연차로 성공적으로 비행했다고 발표한 후 주가는 29.10% 상승했다.</li>
<li>크리네틱스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>)은 JP모건이 <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 47달러에서 54달러로</a> 상향 조정한 후 주가는 21.18% 상승했다.</li>
<li>다인 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>)은 JP모건이 주식에 대해 비중확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 39달러에서 43달러로</a> 높인 후 주가는 19.75% 상승했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 지난주 17.24% 급등했다.</li>
<li>플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주가는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">최근 소비자물가지수(CPI) 발표</a> 이후 전기차 관련주가 상승하면서 16.51% 상승했다. 미국 에너지부는 또한 폐쇄되었거나 위험에 처한 11개의 자동차 시설을 전기 자동차와 공급망 제조를 위해 전환하는 데 17억 달러를 투자한다고 발표했다.</li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 15.56% 상승했다. 6월 중국의 수출이 증가한 것을 계기로 중국 관련 주식이 상승했다.</li>
</ol>
기타 읽어볼 만한 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%eb%b0%94%ec%9d%b4%eb%91%90%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-11%ea%b0%9c%ec%9d%98-%eb%8c%80/" target="_blank" rel="noopener">리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)</a></li>
<li><a href="https://kr.benzinga.com/news/%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4%ec%99%80-%eb%8d%b8%ed%83%80-%ed%95%ad%ea%b3%b5%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10/" target="_blank" rel="noopener">넷플릭스와 델타 항공은 지난주 최악의 성과를 보인 10대 대형주 중 일부 (7월 7일-7월 13일)</a></li>
</ul>
Photo Courtesy of QuantumScape
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Apogee Therapeutics

뉴스

에 대한 최신 뉴스 Apogee Therapeutics (NASDAQ:APGE) 주식

월요일, 7월 15, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌